Legal & General Group’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.09M | Sell |
47,032
-8,043
| -15% | -$782K | ﹤0.01% | 1603 |
|
|
2025
Q4 | $5.9M | Sell |
55,075
-2,301
| -4% | -$244K | ﹤0.01% | 1474 |
|
|
2025
Q3 | $5.79M | Buy |
57,376
+4,695
| +9% | +$436K | ﹤0.01% | 1492 |
|
|
2025
Q2 | $3.33M | Buy |
52,681
+1,523
| +3% | +$93.3K | ﹤0.01% | 1743 |
|
|
2025
Q1 | $2.71M | Sell |
51,158
-645
| -1% | -$35.8K | ﹤0.01% | 1814 |
|
|
2024
Q4 | $2.9M | Buy |
51,803
+951
| +2% | +$52.5K | ﹤0.01% | 1829 |
|
|
2024
Q3 | $2.66M | Buy |
50,852
+1,081
| +2% | +$51.8K | ﹤0.01% | 1855 |
|
|
2024
Q2 | $2.04M | Buy |
49,771
+2,355
| +5% | +$94K | ﹤0.01% | 1942 |
|
|
2024
Q1 | $2.05M | Buy |
47,416
+588
| +1% | +$25.7K | ﹤0.01% | 1932 |
|
|
2023
Q4 | $2.15M | Buy |
46,828
+3,674
| +9% | +$116K | ﹤0.01% | 1913 |
|
|
2023
Q3 | $989K | Buy |
43,154
+501
| +1% | +$11.2K | ﹤0.01% | 2195 |
|
|
2023
Q2 | $703K | Buy |
42,653
+25,534
| +149% | +$461K | ﹤0.01% | 2344 |
|
|
2023
Q1 | $305K | Buy |
17,119
+2,323
| +16% | +$58.3K | ﹤0.01% | 2447 |
|
|
2022
Q4 | $431K | Buy |
14,796
+5,028
| +51% | +$129K | ﹤0.01% | 2373 |
|
|
2022
Q3 | $239K | Sell |
9,768
-2,479
| -20% | -$46.1K | ﹤0.01% | 2560 |
|
|
2022
Q2 | $51K | Sell |
12,247
-1,016
| -8% | -$5.56K | ﹤0.01% | 2998 |
|
|
2022
Q1 | $153K | Hold |
13,263
| – | – | ﹤0.01% | 2759 |
|
|
2021
Q4 | $132K | Hold |
13,263
| – | – | ﹤0.01% | 2850 |
|
|
2021
Q3 | $173K | Buy |
13,263
+6,811
| +106% | +$104K | ﹤0.01% | 2731 |
|
|
2021
Q2 | $127K | Sell |
6,452
-4
| -0.1% | -$83 | ﹤0.01% | 2665 |
|
|
2021
Q1 | $137K | Buy |
6,456
+1,335
| +26% | +$38.7K | ﹤0.01% | 2529 |
|
|
2020
Q4 | $152K | Sell |
5,121
-56
| -1% | -$1.42K | ﹤0.01% | 2481 |
|
|
2020
Q3 | $112K | Sell |
5,177
-1,463
| -22% | -$33.5K | ﹤0.01% | 2455 |
|
|
2020
Q2 | $148K | Buy |
6,640
+799
| +14% | +$15.6K | ﹤0.01% | 2429 |
|
|
2020
Q1 | $85K | Sell |
5,841
-1,303
| -18% | -$23.3K | ﹤0.01% | 2457 |
|
|
2019
Q4 | $164K | Buy |
7,144
+2,927
| +69% | +$65K | ﹤0.01% | 2445 |
|
|
2019
Q3 | $91K | Hold |
4,217
| – | – | ﹤0.01% | 2554 |
|
|
2019
Q2 | $93K | Buy |
4,217
+1,362
| +48% | +$34.4K | ﹤0.01% | 2557 |
|
|
2019
Q1 | $79K | Buy |
2,855
+180
| +7% | +$5.17K | ﹤0.01% | 2564 |
|
|
2018
Q4 | $71K | Hold |
2,675
| – | – | ﹤0.01% | 2567 |
|
|
2018
Q3 | $78K | Buy |
2,675
+850
| +47% | +$26.9K | ﹤0.01% | 2580 |
|
|
2018
Q2 | $57K | Buy |
1,825
+383
| +27% | +$10.5K | ﹤0.01% | 2693 |
|
|
2018
Q1 | $29K | Hold |
1,442
| – | – | ﹤0.01% | 2991 |
|
|
2017
Q4 | $42K | Buy |
+1,442
| New | +$38.1K | ﹤0.01% | 2930 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Legal & General Group's RYTM Position: Q1 2026 in Review
Legal & General Group reduced its Rhythm Pharmaceuticals (RYTM) stake by 15% in Q1 2026, selling an estimated $782K and leaving 47,032 shares worth $4.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1603.
Legal & General Group first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.9M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Legal & General Group held 47,032 shares of Rhythm Pharmaceuticals worth $4.09M as of Q1 2026.
- Legal & General Group sold 8,043 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $782K.
- Rhythm Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1603 holding.
- Legal & General Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Legal & General Group's Rhythm Pharmaceuticals position peaked at $5.9M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.